Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).
Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies to treat autoimmune and inflammatory diseases.
Precede Biosciences is a biotechnology company that provides a blood-based approach to reveal disease-defining transcriptional biology.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs.
Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.
GluBio Therapeutics engages in molecular glue-targeted protein degradation drug discovery.
QuantX Biosciences is a biotechnology company that specializes in computational drug discovery and small-molecule therapeutic products.
NeuShen Therapeutics is a biotechnology company trailblazing the future treatment of neurological and psychiatric disorders.
Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments.
Designing innovative technologies focused on accelerating global access to biotherapeutics.
Syneron is a company that using artificial intelligence and biotechnology to address two significant global challenges.
SciNeuro is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases.
Akura Medical is developing a next-generation thrombectomy device that aims to simplify thrombectomy through an easy-to-use.
Fine Vision is a provider of solutions for ophthalmic illnesses.
Starna Therapeutics developing tissue selective targeted RNA therapies for unmet patient needs.
Ronovo Surgical is an emerging medtech company focused on innovating minimally invasive (MIS) and digital surgery.
ArriVent develops pharmaceutical products to cure presently untreatable cancer.
Kelun Biotech is a biopharmaceutical company that focuses on the research and development, production and sales of innovative drugs.
OTR Therapeutics is a biotechnology company developing platform-based treatments using modular RNA and delivery systems.
Enchannel Medical is a global innovation platform that provides a one-stop atrial fibrillation treatment solutions.
Heyuan Medical Devices is the Enterprise service provider.
Dizal Pharma is a biotechnology company that conducts research for the treatment of cancer and immunological diseases.
Novlead Biotech contributes to a safer and healthier human well-being through our technological innovations.
Lilly Asia Ventures has invested in 102 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Lilly Asia Ventures's top investment sectors include Biotechnology, Health Care, Medical, Biopharma, Therapeutics. The firm invests across 14 different industry categories.
Among tracked funding rounds, Kelun Biotech received $250.0M in a Post Ipo Equity round. Lilly Asia Ventures's total known invested capital is $7.8B.
Lilly Asia Ventures's average investment size is $88.3M across its portfolio of 102 companies.
Recent Lilly Asia Ventures portfolio additions include Caldera Therapeutics, Sonoma Biotherapeutics, Precede Biosciences, Alector, NextCure. These companies were founded in 2020 or later.